This promotional meeting is organised and funded by Novartis Pharmaceuticals UK Limited.
UK | March 2022 | 193547
Entresto (sacubitril/valsartan) is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.UK/yellowcard (UK).
If you have a question about a product, please contact Medical Information on 01276 698370 or by email at email@example.com
To learn about your data privacy rights and the use of your personal information, we invite you to read our General Privacy Notice for Business Partners.